AMRI And UAlbany’s RNA Institute Collaborate To Speed Development Of New RNA-Based Therapeutics
ALBANY, N.Y.— Albany Molecular Research, Inc. (AMRI) and The RNA Institute at the University at Albany have entered into a novel collaboration to advance the discovery and development of RNA-based therapeutics and research tools.
RNA-based therapeutics offer very new approaches to health. At this time, tools for assessing and developing RNA-based therapeutics still need to be developed, validated, and made more standardized and efficient. The RNA Institute fills this gap, as it possesses the intellectual research and development capabilities to design and create new tools, including assays, for the pharma and biopharma industry.
AMRI, an Albany, N.Y.-based global contract research and manufacturing organization, recognized industry-wide for drug discovery and development expertise, provides a deep portfolio of products, services, and extensive experience to help refine and implement cost-effective and scalable solutions in many areas for the pharmaceutical and life science industry, across multiple therapeutic modalities, including RNA-based therapeutics. As the science of RNA-based therapies evolves from discovery to manufacturing, there is a need to engineer new technologies and platforms to efficiently assess these entities and implement GLP/GMP standards and quality assays.
“We are excited to work with UAlbany’s RNA Institute to focus on improving RNA-based therapeutics,” said Christopher Conway, Senior Vice President, Discovery & Development Services. “We look forward to collaborating with the Institute’s scientists in this exciting new area to continue to improve and make available RNA research tools for the broader drug discovery and development community, with the goal to ultimately see these discoveries translate to patients in a clinical setting.”
“This agreement is a first-of-its-kind between an academic institute or center and a contract research organization,” said Dr. Paul Agris, Director, The RNA Institute. “The Institute, because of its unique mission of science-driven technology development, will provide RNA technology advancement, new assays and materials that AMRI will use in support of their drug and diagnostics discovery programs.”
Through the agreement, RNA Institute-developed research tools and quality control and assessment standards will be shared with AMRI to refine, validate, and link commercial partners to support client research and development. This collaboration, and AMRI’s established relationships throughout the health research community, will facilitate additional RNA Institute partnerships that will advance the research and development of new analytical tools for RNA-based therapeutics. AMRI targets strategic relationships to access key technologies and experts that enhance customer solutions and outcomes.
“We are delighted to be working with AMRI and confident our agreement with them will lead to important advances in biomedicine, while also creating new opportunities, including training and jobs for New York,” said Dr. Agris.
About The RNA Institute
The RNA Institute, working in collaboration with global academic and corporate researchers, fosters a fertile, dynamic research environment that promotes the development of RNA tools and technologies to address challenging human health problems. Since its inception in 2009, federal, state and private investments have resulted in a significant expansion of faculty, research staff, labs and instrumentation, generating increased training and employment for graduate students and post-doctoral workers in RNA human health research. A world-class scientific staff; an array of advanced equipment in a mobile; modern lab infrastructure; public-private collaborations; and a dedication to scientific mentorship advance research that demonstrates broad application.
RNA-based therapeutics offer very new approaches to health. At this time, tools for assessing and developing RNA-based therapeutics still need to be developed, validated, and made more standardized and efficient. The RNA Institute fills this gap, as it possesses the intellectual research and development capabilities to design and create new tools, including assays, for the pharma and biopharma industry.
AMRI, an Albany, N.Y.-based global contract research and manufacturing organization, recognized industry-wide for drug discovery and development expertise, provides a deep portfolio of products, services, and extensive experience to help refine and implement cost-effective and scalable solutions in many areas for the pharmaceutical and life science industry, across multiple therapeutic modalities, including RNA-based therapeutics. As the science of RNA-based therapies evolves from discovery to manufacturing, there is a need to engineer new technologies and platforms to efficiently assess these entities and implement GLP/GMP standards and quality assays.
“We are excited to work with UAlbany’s RNA Institute to focus on improving RNA-based therapeutics,” said Christopher Conway, Senior Vice President, Discovery & Development Services. “We look forward to collaborating with the Institute’s scientists in this exciting new area to continue to improve and make available RNA research tools for the broader drug discovery and development community, with the goal to ultimately see these discoveries translate to patients in a clinical setting.”
“This agreement is a first-of-its-kind between an academic institute or center and a contract research organization,” said Dr. Paul Agris, Director, The RNA Institute. “The Institute, because of its unique mission of science-driven technology development, will provide RNA technology advancement, new assays and materials that AMRI will use in support of their drug and diagnostics discovery programs.”
Through the agreement, RNA Institute-developed research tools and quality control and assessment standards will be shared with AMRI to refine, validate, and link commercial partners to support client research and development. This collaboration, and AMRI’s established relationships throughout the health research community, will facilitate additional RNA Institute partnerships that will advance the research and development of new analytical tools for RNA-based therapeutics. AMRI targets strategic relationships to access key technologies and experts that enhance customer solutions and outcomes.
“We are delighted to be working with AMRI and confident our agreement with them will lead to important advances in biomedicine, while also creating new opportunities, including training and jobs for New York,” said Dr. Agris.
About The RNA Institute
The RNA Institute, working in collaboration with global academic and corporate researchers, fosters a fertile, dynamic research environment that promotes the development of RNA tools and technologies to address challenging human health problems. Since its inception in 2009, federal, state and private investments have resulted in a significant expansion of faculty, research staff, labs and instrumentation, generating increased training and employment for graduate students and post-doctoral workers in RNA human health research. A world-class scientific staff; an array of advanced equipment in a mobile; modern lab infrastructure; public-private collaborations; and a dedication to scientific mentorship advance research that demonstrates broad application.